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Available online 25 April 2016Introduction: Continuous video-electroencephalographic (EEG)monitoring remains the gold standard for seizure
liability assessments in preclinical drug safety assessments. EEG monitored by telemetry was used to assess the
behavioral and EEG effects of noribogaine hydrochloride (noribogaine) in cynomolgus monkeys. Noribogaine is
an iboga alkaloid being studied for the treatment of opioid dependence.
Methods: Six cynomolgus monkeys (3 per gender) were instrumented with EEG telemetry transmitters.
Noribogaine was administered to each monkey at both doses (i.e., 160 and 320 mg/kg, PO) with an interval be-
tween dosing of at least 6 days, and the resulting behavioral and EEG effects were evaluated. IV pentylenetetrazol
(PTZ), served as a positive control for induced seizures.
Results: The administration of noribogaine at either of the doses evaluatedwas not associatedwith EEG evidence of
seizure or with EEG signals known to be premonitory signs of increased seizure risk (e.g., sharp waves, unusual
synchrony, shifts to high-frequency patterns). Noribogaine was associated with a mild reduction in activity levels,
increased scratching, licking and chewing, and some degree of poor coordination and related clinical signs. A single
monkey exhibited brief myoclonic movements that increased in frequency at the high dose, but which did not
appear to generalize, cluster or to be linked with EEG abnormalities. Noribogaine was also associated with emesis
and partial anorexia. In contrast, PTZ was associated with substantial pre-ictal EEG patterns including large ampli-
tude, repetitive sharp waves leading to generalized seizures and to typical post-ictal EEG frequency attenuation.
Interpretation: EEG patterns were within normal limits following administration of noribogaine at doses up to
320mg/kgwith concurrent clinical signs that correlatedwith plasma exposures and resolved by the endof themon-
itoring period. PTZwas invariably associatedwith EEG paroxysmal activity leading to ictal EEG. In the current study,
a noribogaine dose of 320 mg/kg was considered to be the EEG no observed adverse effect level (NOAEL) in con-
scious freely moving cynomolgus monkeys.







Noribogaine is the primary human metabolite of ibogaine, an alka-
loid (Fig. 1) extracted from the root bark of the West African shrub
Tabernanthe iboga (Maciulaitis, Kontrimaviciute, Bressolle, & Briedis,
2008). The beneﬁts of ibogaine in the treatment of addiction for45 Armand Frappier, Laval, QC
.
. This is an open access article undermultiple drugs of abuse (e.g., cocaine, morphine, heroin, alcohol, and
nicotine)were documented as early as the 1960's but has since seen fur-
ther conﬁrmation in rodent and human experimentation (Goutarel,
Golnhoffer, & Siddens, 1993; Alper, Lotsof, Frenken, Luciano, &
Bastiaans, 1999; Baumann, Pablo, Ali, Rothman & Mash, 2001;
Maciulaitis et al., 2008). However, despite the apparent anti-addictive
properties of ibogaine, its use in addiction therapy is limited due to its
associated severe side effects, which include hallucination, bradycardia,
whole-body tremors and ataxia (Alper, Lotsof, & Kaplan, 2008; Glick,
Maisonneuve, & Szumlinski, 2000; Maas & Strubelt, 2006; Maciulaitisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Noribogaine is the demethylated metabolite of ibogaine (12-Methoxyibogamine).
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chrome P4502D6 (CYP2D6) into noribogaine (Obach, Pablo, & Mash,
1998) a metabolite that, unlike ibogaine, does not produce tremors
and/or ataxia (Baumann, Rothman, Pablo &Mash, 2001). Investigations
using rats have shown that noribogaine mediates ibogaine-like anti-
addictive effects inducing long-lasting decreases in morphine, nicotine,
cocaine and alcohol self-administration (Carnicella, He, Yowell, Glick, &
Ron, 2010; Chang, Hanania, Mash, & Maillet, 2015; Glick, Kuehne,
Maisonneuve, Bandarage, & Molinari, 1996) as well as possessing high
drug permeability across the blood–brain barrier (Pearl, Hough, Boyd,
& Glick, 1997). A greater understanding of the effects of noribogaine
activity on central nervous system (CNS) function in higher ordermam-
malian species, which possesses greater comparative anatomical and
pharmacological value to humans, is considered useful during drug
development.
CNS safety pharmacology studies in large animals (e.g. dogs, nonhu-
man primates) often use electroencephalographic (EEG) monitoring
systems. Technological advances have paired EEG recordings with
telemetry (Authier et al., 2014; Kramer & Kinter, 2003) and/or integrat-
ed video systems (Authier et al., 2009) during drug safety testing. To this
end, we assessed the neuro-behavioral effects of noribogaine in
cynomolgus monkeys using video-EEG monitoring.
2. Methods
2.1. Statement on use and care of animals
During this investigation, care and use of animals were conducted in
accordancewith principles outlined in the current Guide to the Care and
Use of Experimental Animals published by the Canadian Council on
Animal Care and the Guide for the Care and Use of Laboratory Animals
published by the Institute of Laboratory Animal Resources. CiToxLAB's
facility is AAALAC accredited and the procedures were reviewed and
approved by the Institutional Animal Care and Use Committee prior to
conduct. All procedures were conducted as per Standard Operating
Procedures (SOPs) in place.
2.2. Animals and environment
All animals were housed under standard laboratory conditions with
controlled temperature (21 ± 3 °C), humidity (30%–70%), 12 h light/
dark cycle and 10–15 air changes per hour. Temperature and relativeFig. 2. Normal pre-treatment EEG during non-rapid eye movement sleep stage II (K-comphumidity were monitored continuously. The animals were provided a
standard certiﬁed commercial primate chow (CertiﬁedHi-Fiber Primate
Diet 7195CTM, Harlan Teklad, Madison, WI, USA) twice daily and
municipal tap water (which has been exposed to ultraviolet light and
puriﬁed by reverse osmosis) via an automatic watering system or
water bottles ad libitum. On dosing days, feeding was done 1–3 h
prior to and 4–6 h after noribogaine administration. Six (6; 3 males/3
females) cynomolgus monkeys (Macaca fascicularis), aged approxi-
mately 2 years andweighing approximately 2.6–2.9 kg at the beginning
of the study were used.
2.3. Surgical instrumentation
Cynomolgus monkeys were previously surgically cannulated with a
catheter inserted into the femoral vein and were surgically prepared
with telemetry transmitters (TL11M2-D70-EEE, DSI, St-Paul, MN, USA)
as described previously (Authier et al., 2009). A prophylactic antibiotic
(Cefazolin, Novopharm, Toronto, ON, Canada, 30 mg/kg) was adminis-
tered by intravenous (IV) injection at least 15–20 min prior to surgery
and every 2 h post-injection for a maximum of 3 doses. Pre-emptive
analgesia was attained via a transdermal Fentanyl patch (Sandoz,
Boucherville, QC, Canada, 12.5 μg/h) placed on the animal the day
prior to surgery and removed 2 days post-surgery. A non-steroidal
anti-inﬂammatory (Meloxicam, Boehringer Ingelheim, Burlington, ON,
Canada, 0.1 mg/kg, SID, SC) was administered for 3 days after surgery.
A local anesthetic (Marcaine, Hospira, Montreal, QC, Canada, 0.4 ml;
Lidocaine, Vetoquinol, Lavaltrie, QC, Canada; 20 mg/ml, 0.4 ml) was
injected subcutaneously in 6–10 sites distributed over the surgical
sites during the surgery. Animals were placed on a heating pad and
inhaled a mixture of oxygen (O2) and isoﬂurane (AErrane™, Baxter
Corporation, Mississauga, ON, CAN) with the O2 ﬂowmeter and the va-
porizer set at 1.0 L/min and 2.0%, respectively. Respiratory rate was
maintained between 12 and 15 breaths/min with an inspiratory airway
pressure between 18 and 20 cm H2O using a mechanical ventilator
(Hallowell EMC, Pittsﬁeld, MA, USA). During anesthesia, body tempera-
ture and end-tidal CO2 weremonitored continuously. A longitudinal in-
cisionwas performed lateral, but close, to the linea alba, and the internal
abdominal oblique muscle was separated from the aponeurosis of the
transverse abdominus. The telemetry transmitter was placed between
the internal abdominal oblique muscle and the aponeurosis of
the transversus abdominis muscle. The rectus abdominis was sutured
with a simple continuous suture and electroencephalographic (EEG)lex and sleep spindles) in a conscious cynomolgus monkey monitored by telemetry.
Fig. 3. Normal pre-treatment EEG during non-rapid eye movement sleep stage III also known as slow wave sleep in a conscious cynomolgus monkey monitored by telemetry.
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neck. The abdominal skin incision was closed with interrupted buried
sutures and the animal was placed in sternal recumbency to expose
the cranium for the remainder of the surgery. EEG leads were placed
in the 10–20 system to monitor standard bipolar derivations (C3-O1,
C4-O2 and Cz-Oz). A linear groove was made in the cranial cortical
bone to secure the electrodes with surgical glue (Vetbond™, 3M, St-
Paul, MN, USA) and acrylic. Electromyographic (EMG) recordings were
obtained using electrodes sutured to longitudinal muscles in the neck
area and recorded continuously with the telemetry transmitter. A
period of 4 weeks was allowed between the surgery and the start of
experimental procedures. Both the EEG and EMG electrodes were well
tolerated in all animals.
2.4. EEG analysis methods and behavioral monitoring
EEG data were obtained from animals using telemetry transmitter
leads using bipolar derivations (C3-O1, C4-O2 and Cz-Oz). The EEG
was recorded continuously from at least 24 h prior to dosing to at
least 24 h post-dosing completion (Dataquest ART, Data Science Inter-
national, St-Paul, MN, USA). The EEGs were subjected to computer
analysis from at least 30 min pre-dosing to at least 24 h post-dosing
(NeuroScore, Data Science International, St-Paul, MN, USA). Spectral
analysis was performed on 60-s epochs to quantify the absolute and
relative amplitude of EEG frequency bands (delta [0.5–4 Hz], theta [4–
8 Hz], alpha [8–12 Hz], sigma [12–16 Hz], beta [16–24 Hz] and gamma
[24–50 Hz]) and individual frequencies [0.5–127 Hz]. Digital color
cameras (Geovision, Irvine, CA, USA), with daylight and infrared night
vision connected to a computerized system (IBM Intellistation Z pro,
Xeon 3.8 Ghz, 3.5 TB hard drive, New Orchard Road Armonk, NY,
USA), were used for behavioral videomonitoring. Animals were contin-
uously monitored (except when animals were outside of their home
cage for blood collection and/or during data backup). A standard lexicon
was used for description of behavioral observations.
2.5. Statistical analysis
For each parameter, a one-way analysis-of-variance (ANOVA) was
conducted and the residuals were saved. Gaussian distributions wereFig. 4. Normal EEG at Tmax (3.5 h post-dose) following noribogaine oral administratevaluated using the Shapiro–Wilk test on residuals. Whenever the
Shapiro–Wilk test was found to be signiﬁcant (p ≤ 0.001) then the
data were transformed and re-submitted to the analysis. The Levene
test was used to examine the homogeneity of group variances. For the
ANOVA model, if the overall group differences were shown signiﬁcant
(F-Test), then pair-wise comparisons were conducted using Tukey's
test. Data are presented as mean (SD).
2.6. Blood collection for pharmacokinetic analysis
Blood samples (a target of 1.6 ml each) were collected from all ani-
mals at various time points. The pharmacokinetic parameters of
noribogaine were assessed following oral administration of 320 mg/kg
in male and female monkeys at the following time points: pre-dose,
0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 9, 14 and 24 h after dosing. Following single
oral administration at a dose level of 160 mg/kg, blood samples were
collected at pre-dose and 1 h post-dose. Blood samples were collected
using the implanted catheter into tubes containing sodium heparin as
an anticoagulant and kept on wet ice pending centrifugation. The ani-
mals were not restrained and were not taken out of the cage for blood
collection, unless deemed necessary. Samples were centrifuged under
refrigeration (set to 4 °C at 1500g RCF) and placed on dry ice pending
storage in a freezer set to−70 °C until analysis. Non-compartmental
pharmacokinetic analysis was performed on the plasma concentration
data using theWinNonlin version 5.2 software (Pharsight, Corporation,
Cary, NC, USA) and consisted of the assessment of standard parameters
including Tmax, Tlast, Cmax, Clast, AUClast, AUCAll, AUC0−∞ and t1/2.
2.7. Pharmacological treatments
Noribogaine hydrochloride (noribogaine; Dose level: 160 and
320 mg/kg; DemeRx Inc., Fort Lauderdale, FL, USA) and the control
(vehicle) were administered by oral gavage administration in a dose
escalation design. Animals had a wash-out period of at least seven
days between each treatment based on the reported half-life of
noribogaine. The dose volumewas 5ml/kg for all animals, including ve-
hicle controls. The last treatmentwas for positive control, pentylenetet-
razol (PTZ, dose level: 38–65 mg/kg; Sigma-Aldrich, St. Louis, MO, USA)
administered by IV infusion at a dose rate of 10 ml/kg/h via a surgicallyion at 320 mg/kg in a conscious cynomolgus monkey monitored by telemetry.
Fig. 5. Normal EEG at 18 h post-dose (night time) following noribogaine administration at 320 mg/kg in a conscious cynomolgus monkey monitored by telemetry.
Table 1
Time table for PTZ-induced seizurogenic activity in cynomolgus monkeys.






1 53:40 60:19 3:32
2 76:36 83:31 3:10
3 93:29 97:41 3:04
4 81:52 95:20 0:51
5 45:46 55:25 0:38
6 83:36 96:10 0:45
Mean 72:30 81:24 2:00
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(1.0 mg/kg, IV; Sandoz, Boucherville, QC, Canada) was administered.
3. Results
3.1. Behavioral video monitoring and clinical observations
Following administration of noribogaine at 160 mg/kg, 3 out of 6
animals presented clinical signs including excessive scratching and lick-
ing, chewing motion, emesis, partial anorexia (i.e. decreased appetite),
slightly decreased activity level, and brief periods of poor coordination.
A single monkey also exhibited mild and infrequent twitches that
resembled myoclonic jerks as well as periods of muscle tremor. Similar
clinical signs were observed at 320 mg/kg but with higher incidence
and/or severity. The EEG signals associatedwith these eventswere care-
fully reviewed by the boarded certiﬁed neurologist on our team (D.
Paquette) and by an outside pre-clinical EEG expert (J. Arezzo). Both ex-
perts agreed that the observed movements were not related to
cortically-generated sharp waves and had no EEG correlate. At the
high dose, retching, salivation, moderately decreased activity level,
and tremors were also observed. IV infusion of PTZ was associated
with retching, excessive scratching, repeated yawning, excessive
vocalization, salivation, emesis, uncoordination, slightly to severely
decreased activity level, lying on cage ﬂoor, myoclonic jerks, tremors
and/or clonic or tonic convulsions. PTZ induced seizures were self-
limited or successfully controlled with a single dose of diazepam. Body
weights did not present any variations that could be attributed to the
administration of noribogaine at any dose in this study.
3.2. EEG monitoring by telemetry recordings
Animals were evaluated prior to study initiation to conﬁrm normal
patterns of EEG. (Figs. 2 and 3). EEG following noribogaine treatment
at 160 or 320 mg/kg remained within normal limits (Figs. 4 and 5). As
expected, EEG recorded by telemetry in awake moving and sometimes
sleeping monkeys is characterized by a rich mixture of frequencies
and amplitudes and by occasional movement artifacts. The key ﬁnding
in the present study is that there was no evidence either by computer
scanning or by review by experts of signiﬁcantly altered EEG associated
with noribogaine.
EEG paroxysmal activity was invariably noted after PTZ infusion
with an average of 72:30 min post-infusion onset (range from 45:46
to 93:29; Table 1; Fig. 6) corresponding to a mean cumulative dose of
48.33mg/kg. PTZ infusion led to generalized seizures (Fig. 7) conﬁrmed
by behavioral signs (i.e., recumbency, tonic–clonic movements and
evidences of loss of consciousness) and ictal EEG activity (i.e., spike
trains) in all cynomolgus monkeys. Review of EEG traces revealed the
presence of generalized seizure activity at an average of 81:24 min
into the PTZ infusion (range from 55:25 to 97:41; Table 1) representing
a cumulative dose of 54.27 mg/kg. The doses of PTZ required to induce
paroxysmal EEG activity and generalized seizure were comparable to
previously reported data in this nonhuman primate model (Authier
et al., 2009). Continuous infusion of PTZ was associated with episodes
of synchronous neuronal depolarization with increasing amplitudes
leading to generalized convulsions in all animals. PTZ induced seizureswere successfully controlled with a single IV diazepam injection except
for one female animal inwhich the seizurewas self-limiting (Fig. 8). The
post-ictal period was characterized by an immediate and transient
attenuation of all power bands (delta [0.5–4 Hz], theta [4–8 Hz], alpha
[8–12 Hz], sigma [12–16 Hz], beta [16–24 Hz] and gamma [24–
50 Hz]). This attenuation may be attributed, at least partially, to IV
administration of diazepam but also to typical postictal EEG changes.
3.3. Pharmacokinetic analysis
Plasma concentrations at 1 h following oral administration of
noribogaine at 160 and 320 mg/kg were similar in both genders. The
plasma concentrations were generally variable between animals as
well within the same time points. After the administration of the high
dose (320mg/kg), themaximumplasma concentrations of noribogaine
were achieved between 2.5 and 24 h post-dosing inmales and between
1 to 9 h in females with mean plasma concentrations (Cmax) of 1133 ±
820 and of 1003±423ng/ml inmales and females, respectively. Plasma
concentrations declined slowly thereafter, where the last concentra-
tions (Tlast) correspond to the last time point collected (24 h). Mean
plasma concentrations were similar amongst the two genders (Fig. 9)
with the concentration observed at Tlast (Clast) noted as 615 ± 921
and 300 ± 111 ng/ml in males and females, respectively. The systemic
exposure to noribogaine was similar in both genders as shown by the
male to female Cmax and AUClast ratios of 1.13 and 1.15, respectively.
4. Discussion
This study aimed to assess the CNS safety of noribogaine in cynomol-
gus monkeys by addressing associated behavioral and EEG effects.
Accordingly, this investigation showed that noribogaine administration
(at doses of up to 320 mg/kg) was associated with a range of clinical
signs in cynomolgus monkeys but these clinical signs did not correlate
with abnormal EEG ﬁndings suggestive of seizure activity. Clinical
signs such as tremors, myoclonic jerks or uncoordination/ataxia often
raise concerns related to potential seizurogenic effects of the drug
candidate. Enhanced physiological tremors (Daneault et al., 2011) or
myoclonus (Kojovic et al., 2011) may be considered as pre-ictal signs
but these changes are not speciﬁc to seizure and may also be observed
in normal healthy individuals. As part of the preclinical safety testing
program, EEG is used to characterize brain activity post-dosing and
during clinical signs suggestive of a seizure risk. As noted in the current
study, a variety of clinical signs are not correlated to abnormal EEG
Fig. 6. EEG sharp waves in a male cynomolgus monkey monitored by telemetry at 56 min after onset of IV administration with the positive control PTZ.
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need to be considered. Partial seizure may not be identiﬁed at EEG if
the focal ictal discharge is distant or deep, or involves too small a neuro-
nal aggregate for synchronized depolarization activity to be detected on
the EEG (Smith, 2005). Despite these potential limitations, EEG remains
a valuable tool in preclinical drug safety assessments with the ability to
characterize brain activity during safety pharmacology studies (Bassett
et al., 2014; Metea, Litwak, & Arezzo, 2015; Rachalski et al., 2014).
Recent studies in humans have shown that a single oral dose of
noribogaine (between 3 to 180mg)waswell tolerated but demonstrat-
ed a concentration-dependent increase in the QT interval (Glue et al.,
2016; Glue et al., 2015). Compared to ibogaine, noribogaine displays a
slow pharmacokinetic clearance rate in humans (Glue et al., 2016;
Glue et al., 2015; Maciulaitis et al., 2008; Mash et al., 2001; Mash et al.,
2000) which may be beneﬁcial to its clinical use. Pharmacokinetics of
noribogaine in cynomolgus monkeys in the current study also revealed
a relatively long exposure proﬁle in this species. Noribogaine is a
compound with known poly-pharmacology that partially overlaps
with ibogaine. Principally, both compounds have afﬁnity for serotonin
and dopamine transporters and opioid receptors. However, there are
differences between the two compounds. Noribogaine has marginal
afﬁnities to NMDA, sigma 2 and 5-HT2 receptors compared to ibogaine
(Baumann et al., 2001a; Bowen et al., 1995; Mash, Staley, Baumann,
Rothman, & Hearn, 1995a; Mash et al., 1995b; Staley et al., 1996).
These differences could explain the differences in pharmacology and
toxicology ﬁndings that were reported with these two molecules.Fig. 7. EEG seizure onset at 60 min after onset of IV administration with the poWhile positive control drugs such as PTZ are not mandatory in non-
clinical EEG studies, their inclusion can be used to conﬁrm sensitivity
and speciﬁcity of the model to accurately identify abnormal EEG traces.
Interpretation of EEG traces is known to be a complex task and
electroencephalographers sometimes disagree about whether a partic-
ular pattern is epileptiform and representative of seizures (Fisher,
Scharfman, & deCurtis, 2014). The use of a positive control agent in
seizure liability testing studies can help to mitigate ambiguities in the
EEG interpretation. But the use of a positive control drug, such as PTZ,
a noncompetitive antagonist of theγ-aminobutyric acid (GABA)A recep-
tor complex (Hansen, Sperling, & Sánchez, 2004; Huang et al., 2001)
also presents potential limitations. Animals exposed to positive control
agent cannot be subjected to histopathological evaluations to assess for
neuropathological effects of the drug due to potential confounding
changes induced by the proconvulsive agent (Jandová, Riljak, Pokorný,
& Langmeier, 2007). Furthermore, the use of a positive control may
involve considerations related to application of the 3R (i.e. reduction,
replacement and reﬁnement). It remains that the value of a non-
clinical EEG study to assess drug safety relies on data interpretation
and the inclusion of a positive control can be important to characterize
EEG morphologies in the electrode montage that is used.
When conducting EEG studies, the presence of CNS related clinical
signs such as tremors, ataxia, myoclonus, decreased activity or emesis
can be valuable as early signs of toxicity. While the sequence and expo-
sures at which these clinical signs occur in clinical investigations may
differ from results obtained in non-clinical studies, it remains thatsitive control PTZ in a male cynomolgus monkey monitored by telemetry.
Fig. 8. End of EEG seizure activity (i.e. a polyspike–wave pattern) induced by the positive control PTZ in amale cynomolgusmonkeywith post-ictal attenuation of higher EEG frequencies.
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stopping rulewhen appropriate. In addition, the presence of CNS related
clinical signs might weigh into the decision to select the high dose in a
non-clinical EEG study. When clear and signiﬁcant CNS related clinical
signs are present in the animal model, it may be justiﬁed to stop the
drug dose level escalation prior to attaining a dose inducing seizure.
In conclusion, the current study assessed the functional neurotoxic-
ity of noribogaine when administered orally at doses of 160 and
320 mg/kg to conscious freely moving cynomolgus monkeys with
continuous EEG monitoring by telemetry. While CNS related clinical
signs were observed at both dose levels investigated, no ictal activity
was present in any of the animals. This study illustrates an application
of EEG monitoring in non-human primates for functional neurotoxicity
assessments in noribogaine clinical trials.Conﬂicts of interest
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